Cannabinoid Receptor Function & Alcoholism

Yale University

Status and phase: Completed; Phase 1

Conditions: Alcoholism

Treatments: Drug: THC; Drug: Placebo

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT00624715

0707002888

Details and patient eligibility

About

This study attempts to characterize the effects of tetrahydrocannabinol (THC). Tetrahydrocannabinol is the active ingredient of marijuana, cannabis, "ganja", or "pot". This study will involve healthy volunteers who 1) have no history of alcoholism in their family or 2) have a family history of alcoholism. This study looks at individuals with or without a family history of alcoholism to determine if there is a difference between the two groups in the response to THC.

Enrollment: 29 patients

Sex: All

Ages: 18 to 30 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Exposure to cannabis at least once

Exclusion criteria

• Pregnancy

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Quadruple Blind

---

29 participants in 2 patient groups, including a placebo group

THC

Active Comparator group

Description:

* High dose: 0.036 mg/kg (2.5 mg in a 70 kg individual) IV (in the vein) dissolved in ethanol.Equivalent to smoking a full joint * Low dose: 0.018 mg/kg (1.25 mg in a 70kg individual)IV (in the vein) dissolved in ethanol.Equivalent to smoking ½ of a joint * Very low dose: 0.0036 mg/kg (0.25 mg in a 70 kg individual)IV (in the vein) dissolved in ethanol.Equivalent to smoking 1/10 of a joint

Treatment:

Drug: THC

Placebo

Placebo Comparator group

Description:

Placebo: Small amount of ethanol IV (in the vein), (quarter teaspoon).

Treatment:

Drug: Placebo